Srk-015
Neuromuscular Diseases
Scholar Rock, Inc.Phase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Neuromuscular Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ataluren PTC Therapeutics | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Taldefgrobep Alfa Biohaven Pharmaceuticals, Inc. | Phase 3 | B |
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
Deramiocel Capricor Inc. | Phase 3 | B |
View all 17 →
Same molecule, other indications
Srk-015 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →